By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tobira Therapeutics Inc. 

701 Gateway Boulevard
Suite 300
South San Francisco  California  94080  U.S.A.
Phone: 650-741-6625 Fax: n/a


Company News
Tobira (TBRA) To Host Conference Call At 8:30 A.M. Eastern Time Tomorrow To Discuss CENTAUR Phase 2b Trial Results 7/25/2016 9:30:42 AM
Tobira (TBRA) Stock Loses More Than Half Its Value After Phase IIb Trial Miss 7/25/2016 8:36:53 AM
Tobira’s Cenicriviroc Reduces Inflammation And Fibrosis In Animal Models Of Chronic Liver And Kidney Disease Including NASH 6/28/2016 8:41:37 AM
Tobira’s Cenicriviroc Shown To Reduce Liver Injury In Independent Research Published In The Journal Hepatology 6/17/2016 8:49:46 AM
Tobira To Participate In Two Conferences In June 5/31/2016 9:21:48 AM
Tobira Announces Publication Of Phase 1 Study Results Showing Cenicriviroc Safety In Cirrhotic Patients 5/13/2016 7:37:30 AM
Tobira Reports First Quarter 2016 Financial And Business Results 5/10/2016 7:25:44 AM
Tobira Announces Interim 12-Week Results From The ORION Study 5/2/2016 7:40:13 AM
Tobira Announces Upcoming Presentations On Biomarkers For NASH At Two Scientific Meetings 4/22/2016 6:31:16 AM
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST 4/11/2016 6:35:42 AM